论文部分内容阅读
以肿瘤体积和血清标记浓度作为睾丸癌病人的预后因素,Medical Research Council Working Party的报告就这方面提供了有价值的信息。过去,作者喜欢以其他对预后具有重要意义的特征来评价睾丸癌。近来表明,在睾丸癌与HLA抗原二者关系上有着不一致的看法。虽然De Wolf等报道睾丸癌病人中HLA-DW_7发生率明显增多,但Pollack等则证明HLADR_3发生率减少。这样差异部分是由于回顾性研究造成。因此,作者对65例非精原细胞睾丸癌(NSTT)病人——21例无淋巴结转移,无远处转移,44例术后有淋巴结转移或术后有远处转移的6例HLA—DR抗原发生率进行了前瞻性研究。其中27例为中间恶性畸胎瘤,29例为未分化恶性畸胎瘤,9例为滋养层恶性畸胎瘤。
Using the tumor volume and serum marker concentration as prognostic factors in patients with testicular cancer, the Medical Research Council Working Party report provides valuable information in this regard. In the past, authors like to evaluate testicular cancer in terms of other features of importance to the prognosis. It has recently been shown that there is an inconsistent perception of the relationship between testicular cancer and HLA antigens. Although De Wolf et al reported a marked increase in the incidence of HLA-DW_7 in testicular cancer patients, Pollack et al. Demonstrated a decrease in the incidence of HLADR_3. Part of the difference is due to retrospective research. Therefore, the authors of 65 cases of non-spermatogenic testis cancer (NSTT) patients - 21 patients without lymph node metastasis, no distant metastasis, 44 patients with lymph node metastasis or postoperative distant metastasis of 6 cases of HLA-DR antigen The incidence was prospectively studied. 27 cases were malignant teratoma, 29 cases were undifferentiated malignant teratoma, and 9 cases were trophoblastic teratoma.